Showing 1672 results
-
Story /Patients with glaucoma, which affects 60 million people worldwide, can lose up to 40 percent of their sight before they begin to notice any change in vision.
-
Story /Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.
-
Story /At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.
-
Press release /Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year…
-
Press release /Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)…
-
Press release /Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-…
-
Story /Cardiovascular researcher Jennifer Allport-Anderson describes the personal qualities and decisions that have made her a successful leader.
-
Story /Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.
-
Press release /Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…